Spermatogenic failure characterized by impaired sperm production is a common multifactorial disease with molecular and cytogenetic causes for its extreme phenotype that include azoospermia and severe oliogzoospermia. Recently, a high-resolution array-comparative genomic hybridization analysis of the X chromosome and a subsequent cohort study revealed three X-linked microdeletions (CNV64, CNV67, and CNV69) that were associated with decreased sperm production in a mixed group that included Spanish and Italian males. To confirm their spermatogenic effect, we examined the hemizygous deletions and copy dosage of the MAGE family member A9 (MAGEA9) gene, which is a potential X-linked candidate for the CNV67-related spermatogenic phenotype, to investigate their association with spermatogenic failure in 1722 Han males from southwest China. The individuals in this group consisted of 884 patients with idiopathic azoospermia/oliogzoospermia and 838 controls with normozoospermia. Our results showed that both CNV64 and CNV69 were more common in patients than in controls. Similar to that reported previously, the CNV67 was also identified as being specific to spermatogenic failure in our population, although it was rare. More importantly, the paralog ratio tests and sequence family variant analyses provided evidence that the CNV67 might cause a partial deletion of the proximal copy of the MAGEA9 and suggests that CNV67-related spermatogenic failure may be attributed to the functional defect of the Cancer/Testis gene. Our findings highlight the potential of the Xq-linked CNV67 to serve as a novel detection target in the etiological diagnosis of spermatogenic failure and male infertility, although its pathogenic mechanism remains to be elucidated.
Introduction
In approximately 10%-15% of all patients with severe spermatogenic impairment, the impairment is caused by microdeletions within the azoospermia factor (AZF) region on the Y chromosome. A similar proportion of patients have an additional X chromosome, such as Klinefelter syndrome [1, 2] , which indicates a striking contribution of abnormal sex chromosomes to the pathological condition. Over the past 20 years, studies on the structural mutations of the Y chromosome responsible for spermatogenic failure have led to the detection of AZF microdeletion as the Y-linked etiology of azoospermia and severe oliogzoospermia being used for clinical diagnosis of male infertility [3] , thus significantly improving our ability to recognize the etiology, select assisted reproductive strategies, and inform genetic counseling [4] .
Similar to the Y chromosome, the X chromosome contains genes with exclusive or predominant expression in the testis [5] . The products encoded by these genes play important roles in regulating chromatin modification, mRNA splicing, transcription, translation, and protein ubiquitination [6] . In 2001, a systematic study of mouse spermatogonia revealed that 10 of the 25 genes that are expressed exclusively in germ cells were X-linked, thus suggesting a predominant role for X chromosome genes in premeiotic stages of mammalian spermatogenesis [7] . Further, 33 multicopy gene families of the mouse X chromosome were observed to be predominantly expressed in postmeiotic cells [8] . Moreover, the X-linked ampliconic genes were recently shown to have a similar expression pattern as multicopy genes in germ cells [9] . Taken together, the findings suggest the significance of the X chromosome in the regulation of spermatogenesis. For specific X-linked genes, the pathogenic mutation of the androgen receptor gene responsible for androgen insensitivity syndrome could cause oligozoospermia and azoospermia [10] ; mutation of the testis-expressed 11 gene was shown to result in meiotic arrest and azoospermia [11] . These findings, together with the fact that the male hemizygote of the X chromosome, similar to the Y chromosome, is confronted with a complete loss of gene function in mutant X chromosomes, suggest the potential of the X chromosome as a significant contributor to spermatogenic failure. Although studies investigating the X-linked etiology of spermatogenic failure are limited compared with those examining the Y chromosome, the effects of the X chromosome on male infertility are gaining more attention.
Recently, a high-resolution array-CGH analysis identified a significant deletion burden of the X chromosome in patients with spermatogenic failure relative to normozoospermic controls [12] , and a further population study revealed three recurrent microdeletions (CNV64, CNV67, and CNV69) that were associated with impaired spermatogenesis in Spanish and Italian males, and CNV67 was exclusively found in patients [13] . The importance of the findings is evident when considering the potential clinical implications. However, before this information can be used clinically, it is essential to confirm the effect of these deletions on spermatogenic failure in additional populations. In the present study, we examined these three X-linked microdeletions to investigate their association with impaired spermatogenesis in a Han Chinese population.
Materials and methods

Study population
A total of 1722 unrelated Han Chinese men ranging from 21 to 47 years of age were recruited from Sichuan Province in southwestern China. The general clinical data and blood samples were obtained from the Department of Medical Genetics and the Department of Urology, West China Hospital; the Chengdu Reproductive Medicine Institute, Chengdu Women's and Children's Central Hospital; and the Maternal and Child Health Hospital of Jinjiang District during the period from 2009 to 2016. The subjects consisted of 838 normozoospermic controls with sperm concentration (SC) ≥ 15.0 × 10 6 /ml and 884 patients with spermatogenic failure, including 207 patients with azoospermia, 362 patients with severe oligozoospermia (0 < SC < 5.0 × 10 6 /ml), 315 patients with mild oligozoospermia (5.0 × 10 6 /ml ≤ SC < 15.0 × 10 6 /ml) according to the WHO criteria [14] .
All of the subjects underwent a minimum of two semen analyses.
Patients with known causes of spermatogenic failure, such as obstruction or absence of the vas deferens, orchitis, cryptorchidism, varicocele, hypogonadotrophic hypogonadism or karyotype anomalies, were excluded. None of the subjects carried AZF microdeletions according to the detection results of AZF-specific sequence-tagged sites (STSs) [3] . This study was approved by the Ethics Committee for Clinical Trials and Biomedical Research, West China Hospital, Sichuan University. Informed consent was obtained from all study subjects.
Detection of CNV64, CNV67, and CNV69
Genomic DNA was extracted from peripheral blood samples using DNA isolation kits (TaKaRa, Japan). To ensure comparability of the results, the detection of CNV64, CNV67, and CNV69 was performed with exactly the same method described in a previous report [13] . In brief, each deletion was determined by the absence of three STSs located in the deletion region by a two-step polymerase chain reaction (PCR) process [13] . In the work, the uracil-N-glycosylase was used with a final concentration of 0.02 U/μl in the PCR mixture to avoid the PCR product contamination.
Copy dosage analysis of the MAGEA9 gene
In CNV67 carriers and noncarriers, we analyzed the copy dosage of the MAGE family member A9 (MAGEA9) gene because the involvement of the proximal copy of the gene in the microdeletion has not been definitively identified. This information is essential to obtain a better understanding of the specific effect that the deletion has on spermatogenic failure. According to GRCh38/hg38 Genome Reference, we designed two paralog ratio tests (PRTs) to investigate the copy dosage of the MAGEA9 gene. For PRT1, a pair of primers (PRT1 F/R) was used for amplifying two observed fragments with the length of 112-bp, one of which is located in the intervening sequence between the minimum deletion of CNV67 and the proximal copy of the MAGEA9 (chrX:149580739-149580850), and another is outside of the CNV67 maximum size (chrX:149788540+149788651). Two internal control fragments with a length of 117 bp (chrX: 152703135+152703251 and chrX:152765232-152765348) were [13] . # Fisher exact test for the distribution difference of the CNVs between the patients with impaired spermatogenesis and controls. The significant level α = 0.05. coamplified with the primers. If the observed locus close to the proximal copy of the MAGEA9 is involved in CNV67, the dosage ratio of 112 and 117-bp fragment of the deletion carriers should be 1:2, which could be distinguished from that of 1:1 (2:2) presented in noncarriers of the deletion. For PRT2, a pair of primers (PRT2 F/R) was used to amplify two 185-bp fragments in the proximal and distal copy of the MAGEA9 (chrX:149584247-149584431 and chrX:149784959+149785143) and a 188-bp internal control fragment in the MAGEA4 gene (chrX:151922595+151922782). The deletion of the observed locus in the proximal copy of the MAGEA9 could be detected based on the dosage ratio (1:1) of 185 and 188-bp fragment. For CNV67 carriers and noncarriers, the coamplification of PRT1 F/R and PRT2 F/R was completed, and the PCR products were separated by capillary electrophoresis with an ABI 3700XL (Thermo, USA). The primer sequences are listed in Table S1 . The experimental details of the PRT were similar to those described in a previous report [15] .
We also compared the sequence of the proximal and distal MAGEA9 copies in GRCh38/hg38 Genome Reference. A total of six single-base differences between the copies were chosen to perform sequence family variant (SFV) analysis. They included SFV1 (Cytosine/chrX:149581724 and Thymine/chrX:149787668), SFV2 (Cytosine/chrX:149582146 and Guanine/chrX:149787246), SFV3 (Adenine/chrX:149583708 and Cytosine/chrX:149785684), SFV4 (Cytosine/chrX:149584738 and Thymine/chrX:149784654), SFV5 (Guanine/chrX:149585832 and Adenine/chrX:149783560), and SFV6 (Thymine/chrX:149586329 and Cytosine/chrX:149783063). The PCR products of the six loci from the CNV67 carriers and noncarriers were sequenced directly with the Sanger method to determine their genotypes ( Figure S1 ). The primer sequences are listed in Table S2 .
Statistical analysis
The statistical analyses were performed using the statistical package SPSS 17.0 for Windows (SPSS, USA). Using Fisher exact test, the frequencies of CNV64, CNV67, and CNV69 were compared between the patients and controls, and the genotypes of the SFVs were compared between CNV67 carriers and noncarriers. The comparison of SC, total motile sperm count (TMC), and total sperm count (TSC) between copy number variation (CNV) carriers and noncarriers was performed using the two-sided Mann-Whitney test. Values of P < 0.05 were considered statistically significant.
Results
Association of CNVs with spermatogenic failure
In the present population, we detected three known Xq27-28-linked microdeletions according to the method reported previously [13] . Although the total frequency of the deletions in our study was lower than those of the deletions in the previous report (Fisher exact test, α = 0.05; patient group: Han Chinese, 54/884 vs. Spanish and Italian, 65/627; P = 0.003; control group: Han Chinese, 22/838 vs. Spanish and Italian, 29/628; P = 0.044), the frequency of the deletions between patients and controls was significantly different in our population. As shown in Table 1 , CNV64 and CNV69 were observed in both patients and controls, with significantly higher frequencies in the group of patients relative to controls (Fisher exact test, α = 0.05; CNV64: OR = 1.873, 95% CI = 1.035, 3.388, P = 0.044; CNV69: OR = 2.876, 95% CI = 1.041, 7.948, P = 0.042). CNV67 presented exclusively in the patient group with a statistically significant difference in the frequency relative to the control group (Fisher exact test, α = 0.05; P = 0.031). The results suggest that the microdeletions may exist widely in different populations and support the notion that CNVs are independent risk factors for impaired sperm production due to their nonpopulation-dependent effects on spermatogenesis. In this case, we further analyzed a global risk of the CNVs for spermatogenic failure by combining the data of Spanish and Italian patients [13] . As a result, CNV64 and CNV69 carriers were observed to have a 0.90-and 1.43-fold increased risk for the pathological condition relative to noncarriers, respectively. Furthermore, our results indicated that patients with the two microdeletions presented an increased risk for severe spermatogenic failure In addition, we compared the sperm production, including SC, TSC, and TMC, between CNV carriers and noncarriers. The results showed that the males with any CNV presented lower sperm production relative to noncarriers in the whole study population. The difference was not recurred completely in the patient or control group, which may be due to the limited number of carriers (Table 2) . Interestingly, we found a 32-year-old patient carrying all three CNVs, who presented severe oligozoospermia (SC, 3.8 × 10 6 /ml; TSC, 25.4 × 10 6 ; progressive motility, 7.5%; FSH, 6.75 U/L; LH, 1.56 U/L; Testosterone, 4.41 nmol/L; PRL, 104.95 IU/L; mean testicular volume, 11.0 ml). At present, this case remains a mystery, but it deserves special attention in subsequent studies because it may provide a better understanding in the correlation between the CNVs and spermatogenic phenotype.
Impact of CNV67 to the structure of the proximal copy of the MAGEA9 gene
Using PRT and SFV analyses, we explored the distal structure of the CNV67 minimum size including the proximal copy of the MAGEA9 gene. For the PRT1, the dosage ratio of 1:2 was observed in all six CNV67 carriers, and a total of three dosage ratios, including 1:1, 1:2, and 2:3, were determined in 250 males without the microdeletion ( Figure 1 ). Among the noncarriers, 68 males presented the 1:2 type, with a frequency of 27.2%. When comparing the frequency of the dosage ratio of 1:2 between CNV67 carriers and noncarriers, a significant difference was observed (Fisher exact test, α = 0.05; P = 0.001). With respect to other two dosage ratios of 1:1 and 2:3, the frequency was 61.6% (154/250) and 11.2% (28/250), respectively, in the noncarriers. For the PRT2, all six CNV67 carriers and 250 noncarriers consistently presented the dosage ratio of 2:1.
Further analysis for the six single-base variations between the proximal and distal copy of the MAGEA9 gene found that each of the CNV67 carriers was homozygotic for all six loci (Figure 2) . To investigate the heterozygote frequency of the variations, genotyping of the SFVs was performed in 500 noncarriers, considering the limited polymorphism information content of the loci. As shown in Table S3 , a total of four SFV loci, including SFV1, SFV2, SFV4, and SFV6, were observed to have a heterozygous genotype in the noncarriers. The identification of the SFVs showing population-based polymorphism information should be helpful for the dosage analysis of MAGEA9 copy in other studies. When combining the genotypes of all six SFVs, 241 of the 500 (48.2%) noncarriers showed only a haplotype (the homozygous genotypes in all loci). The frequency of males with single haplotype was significantly different between CNV67 carriers and noncarriers (Fisher exact test, α = 0.05; P = 0.013). A similar difference was observed in the comparison of SFV1 + SFV2 (Fisher exact test, α = 0.05; P = 0.043).
Discussion
The human X chromosome is enriched for a large number of testisspecific genes [5, [7] [8] [9] . Similar to Y chromosome-linked AZF microdeletions, hemizygous gene deletions may also have significantly pathogenic effects on spermatogenesis as a result of the complete loss of the function of the gene product. In the past 5 years, a total of five nontargeting studies investigated copy-number variations associated with spermatogenic failure [12, [16] [17] [18] [19] . Among these, the study focusing on the X chromosome provided more detailed observation on the X-linked deletions, particularly with respect to the validation information of three recurrent microdeletions (CNV64, CNV76, and CNV69) linked to abnormal spermatogenesis (12, 13) . Considering the potential value of these findings in the etiological diagnosis of patients with spermatogenic failure, in the present study, we investigated their associations with spermatogenic failure to confirm the spermatogenic effect that was first reported for the Spanish and Italian populations.
Our results in a Han Chinese cohort showed that both CNV64 and CNV69 carriers indicated a higher risk for impaired sperm production relative to noncarriers. More than that, the concentration of the CNVs in patients with azoospermia and severe oligozoospermia suggests that the deletions may result in an increased risk for severe spermatogenic failure. The findings, together with the exclusive presence of CNV67 in patients with spermatogenic failure, support the notion that the three recurrent X-linked microdeletions confer a significantly negative effect on spermatogenesis. Moreover, we noticed that the total frequency of the deletions in patient or control groups of Han Chinese was lower than those of the Spanish and Italian groups. This suggests a difference in the contribution of these deletions to spermatogenic failure among different ethnic populations. Although both CNV64 and CNV69 do not remove any protein-coding gene or regulatory element [13] , it is possible that their spermatogenic effect may result from the destruction of the Figure 1 . The coamplification of PRT1 and PRT2 to detect the copy dosages of the observed loci close to or in the proximal copy of MAGEA9 gene. PRT1 was used to amplify two 112-bp fragments, including one in the intervening sequence between the minimum deletion of CNV67 and the proximal copy of the MAGEA9 and another outside of the CNV67 maximum size, and two 117-bp internal control fragments. PRT2 was used to amplify two 185-bp fragments in the proximal and distal copies of the MAGEA9 and a 188-bp internal control fragment in the MAGEA4 gene. (A) The dosage ratio of 1:2 for PRT1 and of 2:1 for PRT2. The dosage ratio type was observed in all six CNV67 carriers, suggesting the deletion of observed loci close to the proximal copy of MAGEA9 gene and the presence of observed loci in the proximal copy of MAGEA9 gene. (B) The dosage ratio of 1:1 for PRT1 and of 2:1 for PRT2. The dosage ratio type was observed in 154 of 250 noncarriers of CNV67, suggesting the presence of two observed loci close to or in the proximal copy of MAGEA9 gene. (C) The dosage ratio of 1:2 for PRT1 and of 2:1 for PRT2. The dosage ratio type was observed in 68 of 250 noncarriers of CNV67 with the copy-number variation of the internal control locus of PRT1, suggesting the presence of the two observed loci close to or in the proximal copy of MAGEA9 gene. (D) The dosage ratios of 2:3 for PRT1 and of 2:1 for PRT2. The dosage ratio type was observed in 28 of 250 noncarriers of CNV67 with the copy-number variation of the internal control locus of PRT1, suggesting the presence of the two observed loci close to or in the proximal copy of MAGEA9 gene. spatial organization of chromatin or the disturbance to chromosome pairing of the spermatocyte during meiosis [20] [21] [22] .
Unlike CNV64 and CNV69, CNV67 was found to be a patientspecific microdeletion in our population. The recurrent observation of CNV67 in Spanish, Italian, and Han Chinese patients reinforces the fact that the resulting pathogenicity resembles that of the Y-linked AZF microdeletion. Based on the distal deletion breakpoint analysis reported previously, we further explored the potential influence that CNV67 has on the structure of the proximal copy of the MAGEA9 gene to gain a better understanding of its spermatogenic effect [13] . In the PRT2 analysis, 250 noncarriers showed only one dosage ratio type (2:1), which indicates the dosage consistency of the observed and internal control locus. Therefore, the identical dosage ratio in all six CNV67 carriers suggests the presence of the observed locus in their proximal copies of the MAGEA9. With respect to PRT1, 61.6% of the noncarriers presented a dosage ratio of 1:1, which was an expected ratio due to the presence of two copies of observed locus and the same copy dosage of internal control locus in the reference sequence. Although the dosage ratios of 1:2 (2:4) and 2:3 observed in 38.4% of the noncarriers suggest the copy-number variation of the internal control locus, all six CNV67 carriers presented the same dosage ratio (1:2) in the PRT analysis, showing a significantly different frequency of the dosage ratio relative to noncarriers. In this case, it is highly possible that the dosage ratio of 1:2 in CNV67 carriers is different from that in noncarriers and may actually reflect a deletion of the observed locus close to the proximal copy of the MAGEA9 in the carriers with two copies of internal control locus. In summary, our findings narrowed the distal breakpoint range of the CNV67 minimum size to 10.7 kb (from the distal end of CNV67 to PRT2 locus in the proximal copy of the MAGEA9) from the 28.3 kb reported previously [13] , which will be helpful for eventually locating the distal breakpoint of CNV67.
Further analysis of MAGEA9-linked SFVs identified that four of the six examined loci provided polymorphism information in noncarriers of CNV67, whereas all six of the CNV67 carriers were homozygotic at the loci. Although the observation could not directly suggest the deletion of the SFV loci in the proximal copy of the MAGEA9 considering the high rate of homozygosity at an individual locus, we found a significantly higher frequency of males with single haplotype composed of the six SFV loci in the CNV67 carriers relative to noncarriers. Notably, a similar difference was also observed when comparing the frequency of males with a single haplotype composed of SFV1 and SFV2 between the groups. The results provide statistically significant evidence that suggests the involvement of the proximal copy of MAGEA9 in CNV67, thus further implying that CNV67 may result in the partial deletion of the proximal copy of the MAGEA9, considering the presence of the PRT2 locus in the copy. The MAGEA9 gene, a multicopy member of the MAGEA gene family [23, 24] , is an independently acquired X-linked gene that encodes a Cancer/Testis antigen [9, 24, 25] . It has been suggested that the independently acquired multicopy genes of the X chromosome usually show male germ cell-specific expression and that genes with the Cancer/Testis expression pattern may have a dosage effect on spermatogenesis [9, 12] . These findings, together with the involvement of MAGEA9 in the regulation of gene expression, DNA methylation, and cell apoptosis, suggest an important role of the protein in spermatogenesis and potential correlation with the functional defect of the MAGEA9 copy and spermatogenic failure [26, 27] .
In conclusion, the present study identified the association of CNV64, CNV67, and CNV69 with impaired sperm production, particularly with severe spermatogenic failure, in a Han Chinese population. Our work presented more detailed information on the structure of the proximal copy of the MAGEA9 in the X chromosome carrying CNV67 and provided indirect evidence that suggests the involvement of the MAGEA9 in CNV67. The observation may have potential significance to explain the CNV67 effect as being specific for spermatogenic failure and promoting its clinical application in etiological diagnosis of male infertility. Further population study on the association of the MAGEA9 variation on the X chromosome in the absence of CNV67 with spermatogenic phenotypes may provide more evidence on the contribution of the Cancer/Testis gene to spermatogenic failure.
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Supplemental
